Goldman Sachs Reiterates Sell Rating on PTC Therapeutics (PTCT)

October 9, 2024 5:34 AM EDT Send to a Friend
Goldman Sachs analyst Paul Choi reiterated a Sell rating and $32.00 price target on PTC Therapeutics (NASDAQ: PTCT).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login